Business Wire

New ESMO Guidelines Include FOTIVDA®▼(tivozanib) Recommendation for Patients with Advanced Renal Cell Carcinoma

Jaa

EUSA Pharma (EUSA) welcomes the news that FOTIVDA®▼ (tivozanib) has been included in the new European Society of Medical Oncology (ESMO) clinical practice guidelines for renal cell carcinoma (RCC), published on 21st February 2019.1

In the new guidelines tivozanib is included as a first-line treatment recommendation for advanced RCC (aRCC) clear cell histology patients. The guidelines have also positioned tivozanib as a treatment standard for good (or favourable) risk patients and a treatment option for intermediate risk patients.1

Dr Bernard Escudier, Medical Oncologist and member of the Genitourinary Tumour Board of Gustave Roussy, France, commented “This is excellent news for patients with metastatic RCC. Outcomes in this disease have greatly improved with the introduction of targeted therapies, meaning that patients are living for longer, although currently available therapies can be associated with burdensome toxicities. We are still in need of effective and well tolerated new treatments in metastatic RCC and thus, tivozanib is a welcomed addition. We also look forward to continuing our investigations of potential combination approaches with other therapeutic agents.”

The inclusion of tivozanib in the new guidelines follows the grant of a European Commission (EC) licence in August 2017 for this oral, once-daily,a potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) as first-line treatment of adult patients with aRCC.2

The authorisation within the European Union (EU) was based on evidence from the global, open-label, randomised, multi-centre Phase III trial TiVO-1,which showed that aRCC patients receiving tivozanib experienced improved progression free survival and lower rates of certain adverse events compared to those receiving another VEGFR-TKI, sorafenib.3

“I am pleased that the important European guidelines have been updated to include tivozanib as a recommendation for first line treatment for aRCC,” commented Lee Morley, Chief Executive Officer, EUSA Pharma. “With kidney cancer expected to be one of the fastest increasing cancers over the next ten years, 4 we remain committed to ensuring the availability of tivozanib across the EU in line with the indication as a monotherapy in the first-line setting treatment of aRCC.”

Kidney cancer is the 12th most commonly occurring cancer5 worldwide – the 9th in men and the 14th in women, with over 400,000 new cases in 2018.6 RCC is the most common form of kidney cancer, accounting for approximately 80% of cases.1

a 1340 microgram capsule

-ENDS-

NOTES TO EDITORS

About tivozanib

Tivozanib is an oral, once-daily,b potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI). It is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (aRCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for aRCC.2

An over-expression of VEGF protein, and a resulting increase in tumour blood supply (angiogenesis), is a common feature of RCC.3 VEGFR-TKIs reduce the supply of blood to the tumour and are the recommended first-line treatment for advanced RCC in Europe, however, patients often experience significant side effects including fatigue, diarrhoea, and hand-foot syndrome.

In the global Phase III trial (TiVO-1)3 of over 500 patients with advanced RCC, tivozanib demonstrated a significant progression free survival (PFS) benefit versus sorafenib (11.9 vs. 9.1 months in the overall patient population [HR, 0.797; 95% CI, 0.639 to 0.993; P =.042], and 12.7 vs. 9.1 months in treatment-naïve patients [HR, 0.756; 95% CI, 0.580 to 0.985; P =.037]).3 There was also an improved side-effect profile versus sorafenib, with significantly fewer patients on tivozanib (14% versus 43%) requiring a dose reduction due to AEs; and less than 5% of patients experiencing severe side effects (grade 3&4), such as diarrhoea, asthenia (physical weakness) and hand-foot syndrome. Hypertension (44%) and dysphonia (21%) were the most commonly reported AEs on tivozanib.3

Under EUSA Pharma’s license agreement with AVEO PHARMACEUTICALS, INC, announced in December 2015, the company holds exclusive commercialisation rights to tivozanib in RCC in Europe and in a number of other territories outside North America, including South America and South Africa. Under the terms of the agreement, EUSA Pharma will undertake and fund the commercialisation of the product in its territories, assuming licensing. AVEO PHARMACEUTICALS, INC retains the rights to commercialise the product in North America. Tivozanib was discovered by Kyowa Hakko Kirin.

b 1340 microgram capsule

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has commercial operations in the United States and Europe, and a wider distribution network in approximately 40 countries around the world. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information, please visit www.eusapharma.com.

References

1 Escudier B, Porta C, Schmidinger M et al. Renal Cell Carcinoma: ESMO Clinical Practice Guidelines For Diagnosis and Treatment Follow Up. Available at: https://www.esmo.org/Guidelines/Genitourinary-Cancers/Renal-Cell-Carcinoma. Last accessed March 2019.

2 European Medicines Agency. Fotivda. Available at: https://www.ema.europa.eu/medicines/human/EPAR/fotivda. Last accessed March 2019.

3 Motzer R J, Nosov D et al. Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. Journal of Clinical Oncology. Volume 31. 2013: 30:3791

4 Cancer Research UK. Kidney cancer rates are increasing, so what’s fuelling the surge? Available at: http://scienceblog.cancerresearchuk.org/2017/04/24/kidney-cancer-rates-are-increasing-so-whats-fuelling-the-surge/. Last accessed March 2019.

5 World Cancer Research Fund, Kidney cancer. Available at: https://www.wcrf.org/dietandcancer/kidney-cancer. Last accessed March 2019.

6 World Cancer Research Fund, Kidney cancer statistics. Available at: https://www.wcrf.org/dietandcancer/cancer-trends/kidney-cancer-statistics. Last accessed March 2019.

Contact information

Simon Goldsborough
Open Health Patient & Brand Communications
Tel +44 (0)207 861 2808

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

COMPUTEX 2019 Kicks Off Tomorrow in Taipei27.5.2019 11:42:00 EESTTiedote

COMPUTEX 2019 officially kicks off on Tuesday with focuses on AI & IoT, 5G, Blockchain, Innovations & Startups, and Gaming & XR. A total of 1,685 exhibitors will showcase their technologies in 5,508 booths, which is a near 10% growth from last year. The keynote speakers reflect this emphasis as AMD, Intel, and Microsoft are getting ready to give talks at COMPUTEX. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005076/en/ Group photo at 2019 COMPUTEX International Press Conference & CEO Keynote (Photo: Business Wire) Exciting Lineup of Keynote Speeches; Technology Giants Gather at the Forum to Share Insights For the first time, a CEO Keynote is incorporated in the international press conference where AMD President and CEO Dr. Lisa Su addresses how the next-generation of computing will drive innovation. AMD will, at the same event, unveil details about upcoming products with its ecosystem partners in Taiwan. AMD will sha

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Shown in a Recent Study to Have Beneficial Effects on Human Health and Well-being27.5.2019 11:00:00 EESTTiedote

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced the results of a recent study conducted by Dr. Octavio L. Perez, adjunct researcher in Integrative Lighting at Mount Sinai Hospital in NYC, NY, USA on the non-visual melanopic stimulus of LED sources. The study showed that the company’s SunLike Series natural spectrum LEDs provide up to 21% more melanopic stimulus than conventional LEDs at 4000K, and the same melanopic stimulus as daylight at 6500K (D65). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005028/en/ Seoul Semiconductor's SunLike Series Natural Spectrum LEDs (Graphic: Business Wire) In addition to the visual effects of light and lighting on people, such as visual acuity and color fidelity, there are also non-visual effects. These non-visual effects can affect human health and well-being in aspects related to sleep, awakeness, alertness, circad

Libelium Integrates Radar Technology with its IoT Devices for Smart Parking Applications27.5.2019 11:00:00 EESTTiedote

Aiming to meet the growing demand for greater precision in smart parking devices, Libelium, the Spanish manufacturer of hardware and IoT solutions, has integrated radar technology in detecting the availability of parking spaces. The new Smart Parking node improves detection and stability performance thanks to a radar sensor which allows precise detection (99%) of vehicles parked over the device that sends the data to the cloud through the LoRaWAN network. IoT technology applied to the detection of parking places can reduce traffic, save fuel, decrease CO 2 emissions and improve the driving experience and habitability of cities. In addition, smart parking devices are being highly demanded by municipalities to check rotation levels in restricted parking areas (taxis, loading and unloading, recharging electric vehicles and disabled areas). First real deployment is already taking place in the city of Huesca (Northern Spain) where 190 nodes are being installed to detect the occupation of pa

2019 Trends to Watch in PV Market: High-efficiency Module27.5.2019 10:00:00 EESTTiedote

Upon the return of SNEC PV Power Expo next month, PV InfoLink will explore the PV product trends and the transition of module output at a seminar held in Shanghai on June 3. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005064/en/ China's Export Destinations and Share of Special Module Exports (Graphic: Business Wire) Titled “2H19 PV Market Outlook and Forecast,” the seminar will feature topics spanning China’s transition to subsidy-free market, PV market outlook and supply chain. PV InfoLink, a leading solar market research firm and host of the seminar, has invited top-tier companies including Jinko, Longi, and GCL-Si to discuss the major issues. As the global PV market grows continuously, China’s module exports had hit a record high of 16 GW in Q1’19, a significant growth from last Q4’s 12 GW. In addition to India and Japan’s traditional high season, China exported 5 GW of modules to the European markets in Q1. Foll

A.P. Moller - Maersk Will Join Traxens27.5.2019 09:30:00 EESTTiedote

Traxens, a company providing high-value data and services for the supply chain industry, and A.P. Moller - Maersk (“Maersk”), the integrated container logistics company, today announced that Maersk will be joining CMA CGM and MSC Mediterranean Shipping Company as a key shareholder and customer of Traxens. Founded in 2012, Traxens has been developing unique solutions for the cargo logistics arena and has created an innovative container monitoring and coordination solution. CMA CGM first invested in the startup in 2012 and was later joined in 2016 by MSC. A milestone in the development of Traxens The agreement will see Maersk invest capital in Traxens, in which it will have similar shareholder rights as CMA CGM and MSC. Maersk also commits to order up to 50,000 Traxens devices, a similar order to those placed earlier by CMA CGM and MSC. Traxens can now further focus on strengthening its solution and drive interoperability based on non-proprietary technologies and open standards. The deve

TYAN Showcases HPC, Storage and Cloud Server Platforms Featuring 2nd Gen Intel® Xeon® Scalable Processors at Computex 201927.5.2019 05:00:00 EESTTiedote

TYAN®, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, will be exhibiting a full line of HPC, storage and cloud computing server platforms that are optimized for HPC, enterprise and datacenter markets at Computex 2019 from May 28th to June 1st, Booth # L0631a in Taipei, Taiwan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005002/en/ TYAN's HPC, Storage and Cloud Computing Server Platforms are Optimized for HPC, Enterprise and Data Center Markets to Deliver Leading Performance (Photo: Business Wire) “The increasingly growing demand for AI is transforming the data center and is resulting in a tremendous amount of data being pulled into big data platforms at massive scale,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s leading portfolio of HPC, storage and cloud server platforms are based on the 2

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme